Aclaris Therapeutics (FRA:8AT) Accumulated Depreciation : €-3.99 Mil (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Accumulated Depreciation?

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Aclaris Therapeutics's quarterly accumulated depreciation declined from Sep. 2023 (€-4.31 Mil) to Dec. 2023 (€-3.82 Mil) but then increased from Dec. 2023 (€-3.82 Mil) to Mar. 2024 (€-3.99 Mil).

Aclaris Therapeutics's annual accumulated depreciation increased from Dec. 2021 (€-3.00 Mil) to Dec. 2022 (€-3.81 Mil) and increased from Dec. 2022 (€-3.81 Mil) to Dec. 2023 (€-3.82 Mil).

Aclaris Therapeutics Accumulated Depreciation Historical Data

The historical data trend for Aclaris Therapeutics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Accumulated Depreciation Chart

Aclaris Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Accumulated Depreciation

Get a 7-Day Free Trial

-1.86

-2.16

-3.00

-3.81

-3.82

Aclaris Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accumulated Depreciation	Get a 7-Day Free Trial															-3.93	-4.07	-4.31	-3.82	-3.99

Aclaris Therapeutics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

Aclaris Therapeutics Accumulated Depreciation Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Accumulated Depreciation provided by GuruFocus.com. Please click on the following links to see related term pages.

Aclaris Therapeutics (FRA:8AT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Accumulated Depreciation

Comparable Companies

Traded in Other Exchanges

ACRS:USA

Address

640 Lee Road, Suite 200, Wayne, PA, USA, 19087

Website

https://www.aclaristx.com

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics (FRA:8AT) Headlines

No Headlines